Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

ICRISAT Biological Science Research Technician Vacancy Available

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER
  • BiotechToday
  • World

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

bioxone December 2, 2020December 2, 2020

Husna, Amity University Kolkata

Oncolytic viruses are genetically engineered for the destruction of cancer or tumour-causing cells specifically. They’re delivered for treatment inside the body via intravenous injection. In 2015, one such oncolytic virus was approved by the FDA for treating skin cancer, melanoma. A major obstacle in the application of oncolytic adenoviruses is that they face a barrier from the human immune system. The antibodies and blood components neutralize the injected adenovirus doses and also send it to the liver, the body’s garbage disposal. Some patients also developed inflammation and infection reaction on the application of oncolytic adenovirus.

Recently these barriers have been overcome by the researchers from the Pharmacology department of Case Western Reserve University. They’ve re-engineered the human adenovirus in such a way that it doesn’t get caught by parts of the innate immune system easily. Dmitry Shayakhmetov, PhD has stated that now it is possible to deliver the modified virus systemically at possible high doses for suppression of the tumour growth and even the life-threatening systemic toxicities or inflammatory reaction won’t get triggered anymore. Furthermore, the re-engineered adenoviruses can be armed with genes and proteins that can stimulate an immunity to cancer. 

The re-engineered adenovirus is therefore a technology which can be customized for various cancer patients and can be used as personalized life-saving therapy to patients with metastatic cancer.  

Also read:None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility

SOURCE: 

https://scitechdaily.com/new-weapon-against-metastatic-cancer-engineered-stealth-bomber-virus/

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged adenovirus cancer engineered oncolytic adenovirus FDA infections inflammation inflammatory reactions injection innate immune system intravenously melanoma metastasis metastatic cancer oncolytic patients skin cancer technology therapy tumour cells tumour growth weapon

4 thoughts on “ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER”

  1. Diwita Roy says:
    December 2, 2020 at 4:00 pm

    Very well written. Illuminating content.

    Reply
  2. Pingback: DRY SWAB-DIRECT RT-PCR TO RAMP UP TEST FREQUENCY - BioXone
  3. sania says:
    December 3, 2020 at 11:23 am

    👍well written

    Reply
  4. Fathima Nifara says:
    December 7, 2020 at 1:54 pm

    As Iam very much interested in cancer biology, I personally like this article and its written in a very comprehensible manner.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

ICRISAT Biological Science Research Technician Vacancy Available

bioxone December 3, 2020

-Shristi Sharma, Team bioXone ICRISAT Biological Science Research Technician Vacancy Available. ICRISAT hiring for research vacancies for BSc Biological Sciences candidates with mentioned qualifications are eligible. Check out all the details posted below on the same:  Name of Job: Research Technician No. of Posts: 01 How to Apply: Candidates should apply on or before 17 […]

Related Post

  • BiotechToday
  • World

GEMys: Genetically Engineered Myeloid Cells Can stop the spread of Cancer?

bioxone April 4, 2021April 4, 2021

Koustav Maiti, Ramakrishna Mission Vivekananda Centenary College, Rahara Cancer can be defined by two properties: 1. They reproduce cells by the violation of normal cell growth and division, and 2. They occupy other regions conserved for other normal cells by the properties of invasion and metastasis. Metastasis is the most important character of cancer cells […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

The Function of ABCG2 in hyperuricemia and gout

bioxone June 24, 2021June 23, 2021

Madhavi Bhatia,NIPER Guwahati Hyperuricemia is a condition with increased uric acid levels in the blood which results in the deposition of monosodium urate crystals in synovial fluid of joints resulting in gout. Increased levels may be caused due to increased hepatic biosynthesis or reduced renal or intestinal excretion of urate. Most of the urate is […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

The Genetics of Glaucoma in Africa

bioxone July 11, 2021July 11, 2021

Saakshi Bangera, DY Patil School of Biotechnology and Bioinformatics Primary open-angle glaucoma (POAG) is the most generic subtype of irreversible blindness. Primary open-angle glaucoma primarily affects the people of African heritage. Among Europeans, the prevalence of POAG is approximately 1%, whereas, in African-Americans, this value ranges between 4-5%. Additionally, individuals of African ancestry experience an […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy